SecBot SecBot
SECBOTREPLAY Home › Report › CMMB

CMMB · Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs…

Chemomab Therapeutics Ltd. · PRESS-RELEASE filed Aug 19, 2026 at 08:26 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Aug 19, 2026 at 08:26 ET

Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no revenue. The planned merger with Scipher Medicine to advance nebokitug into a Phase 2 RA trial is progressing, with closing expected by year-end. The significant EPS miss and lack of revenue highlight the pre-revenue clinical-stage nature of the company, but the merger catalyst provides a potential value inflection point.

  • Q1 2026 EPS of -$0.24 missed consensus of $0.00 by 51.8%
  • No revenue reported for the quarter
  • Planned merger with Scipher Medicine to assess nebokitug in Phase 2 RA trial continues, closing expected by year-end
  • Market cap of $14M with 88% analyst bullish rating

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access